Evol Science Overview
- Founded
- 2014
- Status
- Private
- Latest Deal Type
- Accelerator/Inc
- Investors
- 1
Evol Science General Information
Description
Owner and operator of a biotechnology company intended to identify and therapeutically exploit mechanisms of cancer cell resistance. The company's proteomics platform, metadata analysis and predictive analytics develops new targeted therapies to treat various diseases such as pancreatic cancer, acquired resistance metastatic melanoma and others, enabling doctors to make the deadly cancers survivable.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Application Software
Other Pharmaceuticals and Biotechnology
Primary Office
- 3711 Market Street
- Suite 800
- Philadelphia, PA 19104
- United States
Evol Science Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Accelerator/Incubator | Completed | Generating Revenue |
Evol Science Executive Team (4)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Joseph Driscoll | Co-Founder & Chief Executive Officer | ||
| Vikram Bhattacharjee | Co-Founder & Primary Scientist | ||
| Tim Yen Ph.D | Interim CSO | ||
| Andy Andrews Ph.D | Co-Founder |
Evol Science Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Science Center | Accelerator/Incubator | 000 0000 | 000000 0 |